CpG ODN having immunoregulatory function and use thereof
Provided are an immunomodulatory CpG ODN chemically modified by means of a structure as shown by general formula I and the use thereof. The CpG ODN has an immunostimulatory activity, can stimulate the proliferation of B cells, and produce specific cytokines. The above-mentioned CpG ODN can be used as a vaccine adjuvant alone or in combination with other adjuvants to exert a synergistic effect, and can also be used in the preparation of drugs for preventing or treating tumors, infections, and allergies.
1 . An immunoregulatory CpG ODN with a maximum length of 26 bp comprising a nucleotide sequence selected from SEQ ID NOs: 1-4 and 6, wherein at least one nucleotide in the nucleotide sequence is a phosphorothioated nucleotide.
2 . The immunoregulatory CpG ODN of claim 1 , wherein the immunoregulatory CpG ODN consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-4 and 6, and wherein the nucleotide sequence is a completely-phosphorothioated nucleotide sequence.
3 . A method of preventing or treating tumors, microbial infections or allergies in a subject, wherein the method comprises administering an effective amount of the immunoregulatory CpG ODN of claim 1 to the subject.
4 . The method of claim 3 , wherein the subject is a human or an animal, wherein the animal is a mouse, a rat, a domestic animal, or a domestic bird.
5 . A pharmaceutical composition comprising the immunoregulatory CpG ODN of claim 1 and a pharmaceutically acceptable carrier.
6 . A method of preventing or treating tumors, microbial infections or allergies in a subject, wherein the method comprises administering an effective amount of the pharmaceutical composition of claim 5 to the subject.
7 . A vaccine adjuvant comprising the immunoregulatory CpG ODN of claim 1 .
8 . The vaccine adjuvant of claim 7 , further comprising one or more other adjuvants selected from the group consisting of insoluble aluminum salt colloids, oil-water emulsions, microorganisms and their metabolites, nucleic acids and the analogs thereof, cytokines, immunostimulatory complexes, propolis, or liposomes.
9 . A vaccine comprising the immunoregulatory CpG ODN of claim 1 and an antigen, wherein the antigen is a rabies antigen or a SARS-COV-2 antigen.
10 . The vaccine of claim 9 , wherein the vaccine is a rabies vaccine for a human or an animal, and the immunoregulatory CpG ODN consists of a nucleotide sequence as set forth in SEQ ID NO: 3, wherein the nucleotide sequence is a completely-phosphorothioated nucleotide sequence, and the concentration of the CpG ODN is 0.01 μg/ml-1000 μg/ml.
11 . The vaccine of claim 9 , wherein the vaccine is a SARS-COV-2 vaccine, and wherein the vaccine further comprises an aluminum adjuvant.
12 . The vaccine of claim 11 , wherein the immunoregulatory CpG ODN consists of a nucleotide sequence as set forth in SEQ ID NO: 6, and wherein the nucleotide sequence is a completely-phosphorothioated nucleotide sequence.
13 . The vaccine of claim 10 , wherein the concentration of the CpG ODN is 1 μg/ml-10 μg/ml.
14 . The vaccine of claim 11 , wherein the aluminum adjuvant is aluminum hydroxide adjuvant.
15 . The vaccine of claim 11 , wherein the vaccine is an inactivated SARS-COV-2 vaccine.
16 . The vaccine of claim 14 , wherein the concentration of the antigen is 1 μg/mL-10 g/mL; the concentration of the aluminum hydroxide adjuvant is 1 μg/mL-1000 μg/mL; and the concentration of the immunoregulatory CpG ODN is 1 μg/mL-1000 μg/mL.
17 . A rabies vaccine comprising the vaccine adjuvant of claim 7 .
18 . The rabies vaccine of claim 17 , wherein the concentration of CpG ODN in the rabies vaccine is 0.01 μg/ml-1000 μg/ml.
19 . The rabies vaccine of claim 17 , wherein the concentration of CpG ODN in the rabies vaccine is 1 μg/ml-10 μg/ml.
20 . A SARS-COV-2 vaccine comprising the vaccine adjuvant of claim 7 .
21 . The SARS-COV-2 vaccine of claim 20 , wherein the SARS-COV-2 vaccine is an inactivated SARS-COV-2 vaccine, and the concentration of CpG ODN in the SARS-COV-2 vaccine is 0.01 μg/ml-1000 μg/ml.
22 . The SARS-COV-2 vaccine of claim 20 , wherein the SARS-COV-2 vaccine is an inactivated SARS-COV-2 vaccine, and the concentration of CpG ODN in the SARS-COV-2 vaccine is 1 μg/ml-10 μg/ml.